FI3697794T3 - 3-(5-fluoribentsofuran-3-yyli)-4-(5-metyyli-5h-[1,3]dioksolo[4,5-f]indol-7-yyli)pyrroli-2,5-dionin kiinteitä muotoja - Google Patents
3-(5-fluoribentsofuran-3-yyli)-4-(5-metyyli-5h-[1,3]dioksolo[4,5-f]indol-7-yyli)pyrroli-2,5-dionin kiinteitä muotojaInfo
- Publication number
- FI3697794T3 FI3697794T3 FIEP18797367.2T FI18797367T FI3697794T3 FI 3697794 T3 FI3697794 T3 FI 3697794T3 FI 18797367 T FI18797367 T FI 18797367T FI 3697794 T3 FI3697794 T3 FI 3697794T3
- Authority
- FI
- Finland
- Prior art keywords
- solid form
- theta
- form according
- diffraction pattern
- ray powder
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762572603P | 2017-10-16 | 2017-10-16 | |
| PCT/US2018/056083 WO2019079299A1 (en) | 2017-10-16 | 2018-10-16 | SOLID FORMS OF 3- (5-FLUOROBENZOFURAN-3-YL) -4- (5-METHYL-5H- [1,3] DIOXOLO [4,5-F] INDOL-7-YL) PYRROLE-2,5-DIONE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3697794T3 true FI3697794T3 (fi) | 2026-02-10 |
Family
ID=64110166
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP18797367.2T FI3697794T3 (fi) | 2017-10-16 | 2018-10-16 | 3-(5-fluoribentsofuran-3-yyli)-4-(5-metyyli-5h-[1,3]dioksolo[4,5-f]indol-7-yyli)pyrroli-2,5-dionin kiinteitä muotoja |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US11407759B2 (enExample) |
| EP (2) | EP4740944A3 (enExample) |
| JP (2) | JP7776258B2 (enExample) |
| KR (1) | KR102891811B1 (enExample) |
| CN (1) | CN111315748B (enExample) |
| AU (1) | AU2018352384B2 (enExample) |
| CA (1) | CA3074037A1 (enExample) |
| DK (1) | DK3697794T3 (enExample) |
| ES (1) | ES3064009T3 (enExample) |
| FI (1) | FI3697794T3 (enExample) |
| IL (1) | IL273920B2 (enExample) |
| MX (1) | MX2020003431A (enExample) |
| PL (1) | PL3697794T3 (enExample) |
| PT (1) | PT3697794T (enExample) |
| WO (1) | WO2019079299A1 (enExample) |
| ZA (1) | ZA202002740B (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11407759B2 (en) * | 2017-10-16 | 2022-08-09 | Actuate Therapeutics Inc. | Solid forms of 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione |
| KR20210038429A (ko) * | 2018-05-17 | 2021-04-07 | 액투에이트 테라퓨틱스 인크. | 글리코겐 신타제 키나제 3 형태 베타 억제제를 사용한 특발성 폐 섬유증의 치료 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2673368C (en) | 2006-12-19 | 2014-10-28 | The Board Of Trustees Of The University Of Illinois | 3-benzofuranyl-4-indolyl maleimides as potent gsk3 inhibitors for neurogenerative disorders |
| KR20250070131A (ko) | 2017-08-11 | 2025-05-20 | 액투에이트 테라퓨틱스 인크. | 3-(5-플루오로벤조푸란-3-일)-4-(5-메틸-5H-[1,3]디옥솔로[4,5-f]인돌-7-일)피롤-2,5-디온의고체 형태 |
| US11407759B2 (en) * | 2017-10-16 | 2022-08-09 | Actuate Therapeutics Inc. | Solid forms of 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione |
-
2018
- 2018-10-16 US US16/755,903 patent/US11407759B2/en active Active
- 2018-10-16 CA CA3074037A patent/CA3074037A1/en active Pending
- 2018-10-16 PT PT187973672T patent/PT3697794T/pt unknown
- 2018-10-16 MX MX2020003431A patent/MX2020003431A/es unknown
- 2018-10-16 EP EP25225740.7A patent/EP4740944A3/en active Pending
- 2018-10-16 CN CN201880066706.4A patent/CN111315748B/zh active Active
- 2018-10-16 JP JP2020521319A patent/JP7776258B2/ja active Active
- 2018-10-16 ES ES18797367T patent/ES3064009T3/es active Active
- 2018-10-16 IL IL273920A patent/IL273920B2/en unknown
- 2018-10-16 FI FIEP18797367.2T patent/FI3697794T3/fi active
- 2018-10-16 DK DK18797367.2T patent/DK3697794T3/da active
- 2018-10-16 AU AU2018352384A patent/AU2018352384B2/en active Active
- 2018-10-16 PL PL18797367.2T patent/PL3697794T3/pl unknown
- 2018-10-16 WO PCT/US2018/056083 patent/WO2019079299A1/en not_active Ceased
- 2018-10-16 EP EP18797367.2A patent/EP3697794B1/en active Active
- 2018-10-16 KR KR1020207013947A patent/KR102891811B1/ko active Active
-
2020
- 2020-05-13 ZA ZA2020/02740A patent/ZA202002740B/en unknown
-
2022
- 2022-07-01 US US17/855,847 patent/US12116374B2/en active Active
-
2023
- 2023-09-19 JP JP2023151499A patent/JP2024001040A/ja active Pending
-
2024
- 2024-09-10 US US18/830,117 patent/US20250115615A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024001040A (ja) | 2024-01-09 |
| ES3064009T3 (en) | 2026-04-22 |
| ZA202002740B (en) | 2025-12-17 |
| KR20200100615A (ko) | 2020-08-26 |
| AU2018352384B2 (en) | 2023-12-21 |
| AU2018352384A1 (en) | 2020-05-21 |
| US20200239489A1 (en) | 2020-07-30 |
| PT3697794T (pt) | 2026-03-04 |
| JP2020536944A (ja) | 2020-12-17 |
| IL273920B2 (en) | 2025-07-01 |
| JP7776258B2 (ja) | 2025-11-26 |
| WO2019079299A1 (en) | 2019-04-25 |
| CN111315748A (zh) | 2020-06-19 |
| IL273920B1 (en) | 2025-03-01 |
| CA3074037A1 (en) | 2019-04-25 |
| DK3697794T3 (da) | 2026-02-02 |
| MX2020003431A (es) | 2020-07-29 |
| US11407759B2 (en) | 2022-08-09 |
| EP3697794A1 (en) | 2020-08-26 |
| BR112020007538A2 (pt) | 2020-09-24 |
| US20250115615A1 (en) | 2025-04-10 |
| US20220348591A1 (en) | 2022-11-03 |
| EP4740944A2 (en) | 2026-05-13 |
| IL273920A (en) | 2020-05-31 |
| EP4740944A3 (en) | 2026-07-29 |
| CN111315748B (zh) | 2023-06-27 |
| US12116374B2 (en) | 2024-10-15 |
| EP3697794B1 (en) | 2025-12-24 |
| PL3697794T3 (pl) | 2026-04-07 |
| KR102891811B1 (ko) | 2025-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI2534153T4 (fi) | 8-fluori-2-{4-[(metyyliamino}metyyli]fenyyli}-1,3,4,5-tetrahydro-6h-atsepino[5,4,3-cd]indol-6-onin suoloja ja polymorfeja | |
| RU2019101220A (ru) | Кристаллические формы соединения триазолопиримидина | |
| CN113474349B (zh) | 作为nrf2活化剂的羟基吡啶并氧氮杂环庚三烯 | |
| RU2020121150A (ru) | Твердые формы ингибитора калликреина плазмы и его солей | |
| Liao et al. | Design and synthesis of novel soluble 2, 5-diketopiperazine derivatives as potential anticancer agents | |
| CY1118107T1 (el) | Παραγωγα ετεροαρυλιου ως διαμορφωτες αλφα7 nachr | |
| JP2016528179A5 (enExample) | ||
| JP2021504310A5 (enExample) | ||
| JP2010500293A5 (enExample) | ||
| CN104220437B (zh) | α2肾上腺素受体激动剂 | |
| RU2015118581A (ru) | Лиофилизированные препараты мелфалана флуфенамида | |
| RU2017142958A (ru) | Кристаллы азабициклического соединения | |
| FI3665176T3 (fi) | 3-(5-fluoribentsofuran-3-yyli)-4-(5-metyyli-5h-[1,3]dioksolo[4,5-f]indol-7-yyli)pyrroli-2,5-dionin kiinteitä muotoja | |
| FI3317264T3 (fi) | (S)-[3,4-difluori-2-(2-fluori-4-jodifenyyliamino)fenyyli][3-hydroksi-3-(piperidin-2-yyli)atsetidin-1-yyli]metanonin kiteinen fumaraattisuola | |
| RU2019133577A (ru) | ТВЕРДАЯ ФОРМА (S)-[2-хлор-4-фтор-5-(7-морфолин-4-илхиназолин-4-ил)фенил]-(6-метокси-пиридазин-3-ил)метанола | |
| IL273920B2 (en) | Solid forms of 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5h-[3,1]dioxolo[5,4-f]indol-7-yl)pyrrole-5,2-dione | |
| Zhang et al. | Melohemsines AI, melodinus-type alkaloids from Melodinus hemsleyanus | |
| WO2014164648A4 (en) | Solid state forms of a quinazoline derivative and its use as a braf inhibitor | |
| JP2011515421A5 (enExample) | ||
| JP2017535510A5 (enExample) | ||
| JP2024001040A5 (enExample) | ||
| EP3752500A1 (en) | Solid-state forms of abemaciclib, their use and preparation | |
| EP4217358A1 (en) | Indazoles as hematopoietic progenitor kinase 1 (hpk1) inhibitors and methods of using same | |
| JP2020536944A5 (enExample) | ||
| RU2012136921A (ru) | Твердые формы, содержащие производные циклопропиламида |